Mira Leiwant joined Anika as Vice President, Regulatory Affairs, Quality and Clinical Affairs in October 2019. Most recently, Ms. Leiwant was Vice President of Regulatory Affairs at BTG International (acquired by Boston Scientific Incorporated) where she was responsible for the leadership of Interventional Oncology Regulatory business unit. Prior to her work at BTG, she was the Senior Director of Regulatory and Quality Engineering at Lifecell Corporation where she oversaw the development of and led all Regulatory and Quality Engineering teams for the organization. Ms. Leiwant has also held senior leadership roles at a number of other Medical Device, Life Sciences, and Pharmaceutical organizations including Quality Assurance at Svelte Medical Systems, Inc., Vascular Therapies, and Micell Technologies. She began her career at Cordis Corporation, formerly a Johnson and Johnson company.
Ms. Leiwant holds a M.E. in Mechanical Engineering, Bioengineering option and a B.S. in Mechanical Engineering, Bioengineering option, both from Cornell University, and is a Regulatory Affairs Certification (RAC) holder.